Akums Drugs & Pharmaceuticals Ltd
Akums Drugs & Pharmaceuticals Ltd Share Price Today: Live Updates & Key Insights
Get insights on Akums Drugs & Pharmaceuticals Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Akums Drugs & Pharmaceuticals Ltd Share Price Chart
AKUMS at 10 Jul 2026 06:03 PM Pharmaceuticals
701.95 +43.75(+6.65%)
Lowest Today 657.55
Highest Today 707.40
Today's Open 659.10
Prev. Close 658.20
52 Week High 707.40
52 Week Low 405.00
Akums Drugs & Pharmaceuticals Ltd Fundamentals
Traded Volume: 8,81,145
Market Cap(Cr): 11,048.27
Avg Traded Price 689.09
1 Year return 24.96%
Upper Circuit 707.4
Lower Circuit 657.5
P/E TTM 43.00
P/B Ratio 3.041
Traded Value(Cr) 6185.20
EPS TTM 16.213
Book value/Share 216.410
Dividend Yield 1Y 0.43%
Akums Drugs & Pharmaceuticals Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Akums Drugs & Pharmaceuticals Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Akums Drugs & Pharmaceuticals Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W +10.12%
1M +28.03%
3M +42.75%
1Y +24.96%
YTD +47.61%
Akums Drugs & Pharmaceuticals Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Akums Drugs & Pharmaceuticals Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 6.58L
Day Before Yesterday 7.27L
1W Avg 4.98L
1M Avg 4.69L
3M Avg 3.21L
Akums Drugs & Pharmaceuticals Ltd Technical Details
Akums Drugs & Pharmaceuticals Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 671
Support 2 639
Support 3 621
Pivot Point : 689
Resistance 1 720
Resistance 2 739
Resistance 3 770
Akums Drugs & Pharmaceuticals Ltd Corporate Actions
Akums Drugs & Pharmaceuticals Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Akums Drugs & Pharmaceuticals Ltd’s capital allocation strategies.
All
Ex-Date 03-Jul-2026 Type D Description 1.00/share@50.00% Record Date 03-Jul-2026 Ratio 50.00
Ex-Date 03-Jul-2026 Type D Description 2.00/share@100.00% Record Date 03-Jul-2026 Ratio 100.00
Dividends
Announcement Date 03-Jul-2026 Ex Dividend Date 03-Jul-2026 Dividend(%) 50
Announcement Date 03-Jul-2026 Ex Dividend Date 03-Jul-2026 Dividend(%) 100
Bonus
No Bonus has been declared by AKUMS
Splits
No Split has been declared by AKUMS
Others
Rights No Rights has been declared by AKUMS
Akums Drugs & Pharmaceuticals Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Akums Drugs & Pharmaceuticals Ltd with leading peers in the pharmaceuticals & biotechnology sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Akums Drugs & Pharmaceuticals Ltd's relative performance and valuation against major competitors.
Stock Name Marksans Pharma Ltd ₹272.40 (-1.77%) M. Cap (Cr) 123.44 1 Yr Return (%) +5.23% P/E (TTM) 29.54 PB Ratio 4.08
Stock Name Viyash Scientific Ltd ₹277.80 (-1.16%) M. Cap (Cr) 121.36 1 Yr Return (%) +49.94% P/E (TTM) 101.48 PB Ratio 4.17
Stock Name Procter & Gamble Health Ltd ₹6839.00 (+3.43%) M. Cap (Cr) 113.52 1 Yr Return (%) +20.13% P/E (TTM) 34.73 PB Ratio 21.64
Stock Name Akums Drugs & Pharmaceuticals Ltd ₹701.95 (+6.65%) M. Cap (Cr) 110.48 1 Yr Return (%) +24.96% P/E (TTM) 43.29 PB Ratio 3.33
Stock Name Blue Jet Healthcare Ltd ₹624.05 (+8.62%) M. Cap (Cr) 108.25 1 Yr Return (%) -31.56% P/E (TTM) 43.68 PB Ratio 7.96
Stock Name Sanofi Consumer Healthcare India Ltd ₹4566.70 (+1.34%) M. Cap (Cr) 105.17 1 Yr Return (%) -12.48% P/E (TTM) 40.78 PB Ratio 27.39
Stock Name Strides Pharma Science Ltd ₹1082.60 (+0.61%) M. Cap (Cr) 99.79 1 Yr Return (%) +24.05% P/E (TTM) 17.94 PB Ratio 3.21
Akums Drugs & Pharmaceuticals Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Akums Drugs & Pharmaceuticals Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2026 -2.15 Mar 2025 91.00 Mar 2024 247.91 Mar 2023 94.01
PARTICULARS Investing Activities Mar 2026 -24.97 Mar 2025 -458.84 Mar 2024 -165.44 Mar 2023 -202.17
PARTICULARS Financing Activities Mar 2026 -3.00 Mar 2025 375.38 Mar 2024 -20.74 Mar 2023 89.90
PARTICULARS Net Cash Flow Mar 2026 -30.11 Mar 2025 7.54 Mar 2024 61.72 Mar 2023 -18.26
Akums Drugs & Pharmaceuticals Ltd Shareholding Pattern
This shows the ownership breakdown of Akums Drugs & Pharmaceuticals Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 75.26%
Public 6.29%
Other Institutions 3.41%
FII 1.38%
Mutual Funds 10.95%
About Akums Drugs & Pharmaceuticals Ltd
Akums Drugs and Pharmaceuticals Limited was incorporated vide Certificate of Incorporation dated April 19, 2004 and received a Certificate for Commencement of Business dated May 13, 2004 issued by the RoC.Alkums Drugs & Pharmas are a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. They are into sale of branded pharmaceutical formulations and manufacturing of Active Pharmaceutical Ingredients. Some of the other services include formulation research and development, preparation and filing of regulatory dossiers into the Indian and global markets, and other testing services. Their specialization extends to development and sale of APIs across diverse chemical processes and therapeutic areas such as anti-infective, respiratory and diabetes. In 2004, the Company established first plant for oral dosage commissioned at 19, 20, 21, Sector 6A, Haridwar, Uttarakhand. In 2007, it established dedicated manufacturing site for oral liquid dosage and sterile products both at Haridwar, Uttarakhand. It incorporated Maxcure Nutravedics Limited to venture into nutraceuticals in 2009. In 2010, it dedicated a facility for hormones ; dedicated a facility for cosmetics and dermatology at Haridwar, Uttarakhand. In 2010, it incorporated Akumentis Healthcare Limited to venture into branded formulations.In 2011, it innovated bi-layered sustained release tablets for the first time. In 2012, acquired subsidiary, Pure and Cure Healthcare Private Limited to expand capacity and capabilities. In 2013, it acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities. It established R&D Laboratory in Mumbai, Maharashtra to venture into regulated market in 2015. In 2021, the Company acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs. Further, it acquired Kotdwar Plant in Uttarakhand by Akums Healthcare Limited. In 2022, it acquired facility in Haridwar, Uttarakhand through the subsidiaries, Akums Healthcare Limited and in 2023, acquired Baddi facility in, Himachal Pradesh through Pure and Cure Healthcare Private LimitedFollowing a Scheme of Arrangement on October 17, 2023, Akums Lifesciences Limited got merged with its subsidiary, Pure and Cure Healthcare Private Limited (PCHL) with effect from April 1, 2022. As part of this acquisition, it acquired manufacturing units in Dera Bassi and Lalru in Punjab and Barwala in Haryana, and an R&D centre in Barwala, Haryana and commenced operations in the manufacture and sale of key starting materials, intermediates and APIs. The Company launched an IPO by issuing 27,368,151 equity shares of Rs 2 each by raising funds aggregating to Rs 1857 Crore comprising a fresh issue of 10,037,716 equity shares aggregating to Rs 680 Crore and offer for sale of 17,330,435 equity shares aggregating to Rs 1177 Crore in August, 2024.Akums Healthcare UK Ltd. was incorporated as a foreign wholly owned subsidiary of the Company on 18th March, 2025. The new state-of-the-art facilities at Kotdwar and Haridwar, focusing on Penem anti infectives and general injectables, have enhanced the manufacturing capacity in FY 2025.
Managing Director
SANDEEP JAIN
Registered office 304 Mohan Place LSC Saraswati, Vihar, Delhi, Delhi, 110034
FAX :+91 11 6904 1000
Background
Incorporation Year 2004
Face Value ₹2.00
Market Lot 1
FAQs on Akums Drugs & Pharmaceuticals Ltd
How to buy Akums Drugs & Pharmaceuticals Ltd shares?
To buy Akums Drugs & Pharmaceuticals Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the market cap of Akums Drugs & Pharmaceuticals Ltd?
The company has a market capitalization of ₹11,048.27.
What is the PE & PB ratio of Akums Drugs & Pharmaceuticals Ltd?
PE is 43 and PB is 3.041.
What is the Akums Drugs & Pharmaceuticals Ltd dividend for 2025–26?
For the 2025–26 financial year, Akums Drugs & Pharmaceuticals Ltd declared a final dividend of 0.43% per share.